Yongin-si, South Korea

Yong Seok Lee

USPTO Granted Patents = 2 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2024-2025

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Yong Seok LEE: A Dual Modulator for Pain Treatment

Introduction

Yong Seok LEE, an accomplished inventor based in Yongin-si, South Korea, has made significant contributions to the field of pharmacology through his innovative work. With a focus on developing therapeutic agents for pain relief, LEE's groundbreaking patent demonstrates his commitment to addressing complex medical challenges.

Latest Patents

Yong Seok LEE holds a patent for a "Dual modulator of mGluR5 and 5-HT2A receptor, and use thereof." This innovative patent discloses a unique compound that acts as both a modulator of the mGluR5 receptor and an antagonist of the 5-HT2A receptor simultaneously. This dual action has promising implications as a therapeutic agent for pain management, representing a significant step forward in pain treatment methodologies.

Career Highlights

LEE is currently affiliated with Vivozon, Inc., where he continues to explore new therapeutic avenues in pharmacology. His single patent reflects a dedicated effort to advance understanding and treatment options in the medical field, showcasing his potential impact on future medical innovations.

Collaborations

Throughout his career, Yong Seok LEE has collaborated with notable colleagues, including Dae Kyu CHOI and Hyo Jin KIM. These professional relationships likely contribute to the successful development and implementation of innovative therapies, strengthening the collaborative efforts in research and development at Vivozon, Inc.

Conclusion

In summary, Yong Seok LEE's innovative work on the dual modulator presents a promising development in the realm of pain treatment. His contributions not only emphasize the importance of collaborative research but also underline the potential for advancements in therapeutic agents, paving the way for better patient outcomes in the future.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…